S
Samuel Hellman
Researcher at University of Chicago
Publications - 157
Citations - 19248
Samuel Hellman is an academic researcher from University of Chicago. The author has contributed to research in topics: Radiation therapy & Breast cancer. The author has an hindex of 53, co-authored 156 publications receiving 18869 citations. Previous affiliations of Samuel Hellman include The Advisory Board Company & University of Illinois at Chicago.
Papers
More filters
Journal ArticleDOI
Anatomic Substages of Stage III-A Hodgkin's Disease: A Collaborative Study
Richard S. Stein,Harvey M. Golomb,Charles H. Diggs,Peter Mauch,Samuel Hellman,Peter H. Wiernik,John E. Ultmann,David S. Rosenthal +7 more
TL;DR: Consideration of anatomic substage may aid therapeutic planning for stage III Hodgkin's disease.
Journal ArticleDOI
Assessment of intratumoral vascularization (angiogenesis) in breast cancer prognosis.
TL;DR: Intratumoral vascularization appears to be an early event that is necessary but not sufficient for metastatic progression, but is less good at predicting those at high risk since the 20-year disease-free survival is still 67-70% in those with high microvessel count, so the higher risk group needs to be further stratified using additional prognostic factors.
Important Advances in Oncology 1986
Samuel Hellman,Vincent T. DeVita +1 more
TL;DR: In this paper, a 15-chapter book contains 15 chapters, including: Chromosomal Rearrangements, Genes, and Fragile Sites in Cancer; Clinical and Biologic Implications; New Aspects of Clinical Drug Resistance: The Role of Gene Amplification and The Reversal of Resistance in Drug Refractory Cancer; Control of Gene Expression and the Replication and Pathogenesis of Retroviruses; and Unconventional Fractionation Schemes in Radiotherapy.
Journal ArticleDOI
Engraftment following T-cell-depleted marrow transplantation. I. The role of major and minor histocompatibility barriers.
TL;DR: A murine model for survival and engraftment of bone marrow transplantation across differing histocompatibility barriers is described and survival was poor in allogeneic A/J recipients due to bone marrow failure even at high marrow dose levels.
Journal ArticleDOI
Transcriptional control of viral gene therapy by cisplatin
James O. Park,Carlos A. Lopez,Vinay K. Gupta,Charles K. Brown,Helena J. Mauceri,Thomas E. Darga,Abdullah Manan,Samuel Hellman,Mitchell C. Posner,Donald Kufe,Ralph R. Weichselbaum +10 more
TL;DR: Chemo-inducible cancer gene therapy thus provides a means to control transgene expression while enhancing the effectiveness of commonly used chemotherapeutic agents.